Laboratory of Transmissible Diseases and Biological Active Substances, LR99-ES27, Faculty of Pharmacy, University of Monastir, Monastir, Tunisia.
Infect Agent Cancer. 2012 Nov 12;7(1):31. doi: 10.1186/1750-9378-7-31.
Infectious etiology in lymphoproliferative diseases has always been suspected. The pathogenic roles of human herpesvirus-6 (HHV-6) in acute leukemia have been of great interest. Discordant results to establish a link between HHV-6 activation and the genesis of acute leukemia have been observed. The objective of this study was to evaluate a possible association between HHV-6 infection and acute leukemia in children and adults, with a longitudinal follow-up at diagnosis, aplasia, remission and relapse.
HHV-6 load was quantified by a quantitative real-time PCR in the blood and bone marrow samples from 37 children and 36 adults with acute leukemia: 33 B acute lymphoblastic leukemia (B-ALL), 6 T acute lymphoblastic leukemia (T-ALL), 34 acute myeloid leukemia (AML).
HHV-6 was detected in 15%, 8%, 30% and 28% of the blood samples at diagnosis, aplasia, remission and relapse, respectively. The median viral loads were 138, 244, 112 and 78 copies/million cells at diagnosis, aplasia, remission and relapse, respectively. In the bone marrow samples, HHV-6 was detected in 5%, 20% and 23% of the samples at diagnosis, remission and relapse, respectively. The median viral loads were 34, 109 and 32 copies/million cells at diagnosis, remission and relapse, respectively. According to the type of leukemia at diagnosis, HHV-6 was detected in 19% of the blood samples and in 7% of the bone marrow samples (with median viral loads at 206 and 79 copies/million cells, respectively) from patients with B-ALL. For patients with AML, HHV-6 was present in 8% of the blood samples and in 4% of the bone marrow samples (with median viral loads at 68 and 12 copies/million cells, respectively). HHV-6 was more prevalent in the blood samples from children than from adults (25% and 9%, respectively) and for the bone marrow (11% and 0%, respectively). All typable HHV-6 were HHV-6B species. No link was shown between neither the clinical symptoms nor the abnormal karyotype and HHV-6 activation. A case of HHV-6 chromosomal integration was shown in one patient with AML.
This study confirms the absence of role of HHV-6 in the genesis of acute leukemia but the virus was reactivated after chemotherapy treatment.
淋巴增生性疾病的感染病因一直受到怀疑。人类疱疹病毒-6(HHV-6)在急性白血病中的致病作用引起了极大的关注。然而,目前观察到 HHV-6 激活与急性白血病发生之间的关联尚未得到明确证实。本研究旨在评估 HHV-6 感染与儿童和成人急性白血病之间可能存在的关联,并在诊断、再生障碍、缓解和复发时进行纵向随访。
我们通过定量实时 PCR 检测了 37 名儿童和 36 名成人急性白血病患者的血液和骨髓样本中的 HHV-6 载量:33 例 B 型急性淋巴细胞白血病(B-ALL)、6 例 T 型急性淋巴细胞白血病(T-ALL)、34 例急性髓细胞白血病(AML)。
在诊断时、再生障碍时、缓解时和复发时,血液样本中 HHV-6 的检出率分别为 15%、8%、30%和 28%。病毒载量中位数分别为诊断时 138、再生障碍时 244、缓解时 112 和复发时 78 拷贝/百万细胞。在骨髓样本中,诊断时、缓解时和复发时 HHV-6 的检出率分别为 5%、20%和 23%。病毒载量中位数分别为诊断时 34、缓解时 109 和复发时 32 拷贝/百万细胞。根据诊断时的白血病类型,B-ALL 患者的血液样本中 HHV-6 的检出率为 19%,骨髓样本中为 7%(病毒载量中位数分别为 206 和 79 拷贝/百万细胞)。AML 患者的血液样本中 HHV-6 的检出率为 8%,骨髓样本中为 4%(病毒载量中位数分别为 68 和 12 拷贝/百万细胞)。儿童血液样本中 HHV-6 的检出率高于成人(分别为 25%和 9%),而骨髓样本中 HHV-6 的检出率则相反(分别为 11%和 0%)。所有可分型的 HHV-6 均为 HHV-6B 种。未发现 HHV-6 激活与临床症状或异常核型之间存在关联。在一名 AML 患者中发现了 HHV-6 染色体整合。
本研究证实 HHV-6 与急性白血病的发生无关,但病毒在化疗治疗后被重新激活。